Business Context and Reporting Period
This Form 8-K, filed by Bristol-Myers Squibb Company on November 15, 2001, reports the completion of the sale of its Clairol beauty care business to Procter & Gamble (P&G). The transaction was executed pursuant to a Stock and Asset Purchase Agreement dated May 20, 2001.
Key Financial Metrics
- Transaction Value: $4.95 billion in cash.
- Estimated Gain on Sale: $4.20 billion (calculated as proceeds of $4.95 billion less historical net assets of $463 million and transaction-related liabilities of $287 million).
- Estimated Tax Impact: $1.70 billion in taxes on the preliminary gain.
- Debt Repayment: $1.574 billion of proceeds used to repay outstanding commercial paper.
- Pro Forma Cash Position: Adjusted cash and cash equivalents increased to $6.177 billion (historical $2.801 billion plus proceeds, less debt repayment).
- Pro Forma Total Assets: $27.224 billion.
- Pro Forma Total Liabilities: $14.737 billion.
- Pro Forma Stockholders' Equity: $12.487 billion.
Material Changes Versus Prior Period
The filing presents unaudited pro forma financial information as of September 30, 2001, reflecting the divestiture. Key adjustments include:
- Removal of Clairol's historical net assets ($787 million in total assets and $463 million in net assets).
- Reduction in short-term borrowings by $1.574 billion due to the use of sale proceeds.
- Increase in income taxes payable by $1.70 billion reflecting the tax liability on the gain.
- Recognition of a $4.20 billion gain on the sale, net of transaction costs.
Clairol has been reported as a discontinued operation in the Company's consolidated statements of earnings for the year ended December 31, 2000, and the nine months ended September 30, 2001.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance or management commentary regarding future operational performance beyond the transaction details. The pro forma balance sheet is explicitly stated to be for illustrative purposes only and does not purport to be indicative of the actual financial position that would have occurred if the transaction had been effected on September 30, 2001, nor is it indicative of future financial positions. The summary of the sale is qualified in its entirety by the Purchase Agreement.
Investor Verification Checklist
- Verify the final closing date and any post-closing adjustments to the $4.95 billion purchase price.
- Confirm the actual tax liability recognized versus the estimated $1.70 billion preliminary figure.
- Review the detailed breakdown of the $287 million in transaction-related liabilities (fees, severance, etc.).
- Examine the impact of the divestiture on future revenue streams and R&D focus, given the shift away from consumer beauty care.
- Check subsequent filings for the final accounting treatment of the gain and any deferred tax implications.